Seagen and Springer Nature will hold a global contest for research on drug resistance for urinary tract infections until November 20th
Sep 03, 2025
|
This is the third global research project contest to be held since the start of 2023, allowing participants to freely organize up to 18 urinary tract infectious disease drug resistance genes to suggest product development ideas and clinical research plans. The final selection will receive up to $600,000 (about KRW 830 million) in research funds and receive diagnostic reagents, extraction reagents, consumables, equipment, and related software from Cizen to participate in developing syndromic PCR diagnostic reagents and conduct clinical research.
At the 2024 Nature Awards, which held the contest last year, the research project for rapid detection of pneumococcal drug resistance and virus diagnosis for immunocompromised patients was finally selected.
Regarding the background of the selection of the subject of the contest, Seegene and Springer Nature explained that "UTI is one of the most common infections worldwide, and the importance of rapid and accurate diagnosis is further highlighted due to the increase in antibiotic resistance."The aim is to encourage the development of customized, syndromic PCR-based diagnostic solutions optimized for each country" he explained.
Based on its syndromic quantitative PCR technology and reagent development automation system (SGDDS), Seegene's technology sharing project is a global project to collaborate with representative companies and experts to jointly develop local customized diagnostic products for various diseases of people and animals. Through this, Seegene aims to realize a 'world free from all diseases'.
Park Jik-young, head of the Seegene Diagnostic Reagent Research Institute, said "We will realize Seegene's vision of a 'disease-free world' by discovering creative ideas from researchers around the world and promoting technology sharing projects through continuous cooperation." he said.
Richard Hughes, Vice President of Springer Nature, stated, `We expect this MDx Impact Grant, coupled with the technology sharing business, to contribute to creating an ecosystem where patients around the world can receive faster and more accurate diagnosis.'
This article was translated by Naver AI translator.
